Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2019 to Jun 2024
TKT Stockholders Approve Acquisition by Shire
CAMBRIDGE, Mass., July 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that TKT stockholders approved the
acquisition by Shire Pharmaceuticals Group plc.
(LSE:SHPLSE:Nasdaq:LSE:SHPGYLSE: TSX:LSE:SHQ) for $37 per share in cash, or
$1.6 billion in aggregate value, at the special meeting of stockholders by
voting to adopt the merger agreement that the company entered into with Shire
on April 21, 2005. The transaction is expected to close July 28, 2005.
Lydia Villa-Komaroff, Chairwoman of the Board of TKT said, "We are extremely
pleased with the outcome of today's TKT vote and that the stockholders of TKT
agree that the acquisition by Shire delivers full, fair and immediate cash
value to our stockholders."
The Inspector of Election certified the following voting results with respect
to the proposed Shire acquisition: 18,741,994 shares or approximately 52.6% of
the shares entitled to vote voted "for" the adoption of the merger agreement,
9,890,989 shares or approximately 27.7% voted "against", and 47,416 shares or
approximately 0.1% "abstained".
TKT also announced that it has received written demands for appraisal from
stockholders with respect to 12,318,765 shares of TKT common stock which
represented approximately 34.6% of the outstanding shares of TKT common stock
as of the record date.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements regarding the proposed
transaction between Shire and TKT, and statements regarding the company's
financial outlook, as well as statements about future expectations, beliefs,
goals, plans or prospects, including statements containing the words
"believes," "anticipates," "plans," "expects," "estimates," "intends,"
"should," "could," "will," "may," and similar expressions. There are a number
of important factors that could cause actual results to differ materially from
those indicated by such forward-looking statements, including the failure of
TKT and Shire to consummate the proposed merger for any reason, and including
other factors set forth under the caption "Certain Factors That May Affect
Future Results" in the company's Quarterly Report on Form 10-Q for the quarter
ended March 31, 2005, which are on file with the SEC and which factors are
incorporated herein by reference. While the company may elect to update
forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, even if its expectations
change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Manager, Corporate Communications
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Manager, Corporate
Communications, +1-617-349-0205, both of Transkaryotic Therapies, Inc.
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html